Carling Rachel S, Barclay Zoe, Cantley Nathan, Ghansah Nana, Hogg Sarah L, Horman Alistair, Moat Stuart J, Cowen Simon, Hopley Chris, Deaves Chloe, Whyte Emily
GKT School Medical Education, Kings College London, London, UK.
Biochemical Sciences, Synnovis, Guys & St Thomas' NHSFT, London, UK.
Clin Chem Lab Med. 2025 Feb 4;63(7):1336-1343. doi: 10.1515/cclm-2024-1367. Print 2025 Jun 26.
Management of phenylketonuria (PKU) relies upon life-long monitoring of phenylalanine (Phe) in dried blood spots (DBS), thus comparability of measurements is important. The lack of harmonisation and standardisation between laboratories, combined with the variable quality of patient-collected DBS specimens, are currently preventing this from being achieved. A traceable, matrix-matched Phe certified reference material, common methodology and means to ensure patient collected DBS specimens are of consistent quality would improve comparability between laboratories.
Baseline inter-laboratory (n=15) variation of DBS Phe was determined by triplicate measurement of four DBS materials, on three days. Laboratories prepared and analysed these samples using their routine method of analysis. A sub-set of laboratories (n=5) repeated the process using a common sample preparation and instrument methodology (LC-MS/MS), and three different calibration approaches. Samples prepared on dried blood spot microsampling cards (DBS-MCs) from whole blood, value assigned for Phe concentration by National Measurement Laboratories (NML), were then analysed using the harmonised methodology.
Inter-laboratory co-efficient of variation (CV) differed with calibration approach; internal calibration 27.7 %; in-house aqueous calibration 4.7 %; centrally distributed aqueous calibration, 2.1 %. Inter-laboratory CV was reduced from 8.7 to 2.1 % by using common sample preparation and LC-MS/MS methodology. No significant difference was observed between consensus and assigned values for Phe in the four materials (p>0.05).
This study demonstrates a simple approach to harmonising and standardising DBS Phe measurements, traceable to value assigned materials. Combined with the introduction of DBS-MCs to ensure specimen quality, clinical laboratories can achieve comparability of patient results over time.
苯丙酮尿症(PKU)的管理依赖于对干血斑(DBS)中苯丙氨酸(Phe)进行终身监测,因此测量结果的可比性很重要。目前,实验室之间缺乏协调和标准化,再加上患者采集的DBS标本质量参差不齐,使得这一点难以实现。一种可溯源的、基质匹配的Phe认证参考物质、通用方法以及确保患者采集的DBS标本质量一致的方法,将提高实验室之间的可比性。
通过在三天内对四种DBS材料进行三次重复测量,确定了DBS中Phe的实验室间基线变异(n = 15)。实验室使用其常规分析方法制备和分析这些样本。一组实验室(n = 5)使用通用的样本制备和仪器方法(液相色谱-串联质谱法,LC-MS/MS)以及三种不同的校准方法重复该过程。然后使用统一方法分析从全血在干血斑微量采样卡(DBS-MCs)上制备的样本,这些样本由国家计量实验室(NML)指定Phe浓度值。
实验室间变异系数(CV)因校准方法而异;内部校准为27.7%;内部水溶液校准为4.7%;集中分发的水溶液校准为2.1%。通过使用通用的样本制备和LC-MS/MS方法,实验室间CV从8.7%降至2.1%。在四种材料中,Phe的共识值和指定值之间未观察到显著差异(p>0.05)。
本研究展示了一种使DBS中Phe测量协调一致和标准化的简单方法,该方法可溯源至指定值的材料。结合引入DBS-MCs以确保标本质量,临床实验室可以实现患者结果随时间的可比性。